Aura Biosciences, Inc. Other Operating Activities, Cash Flow Statement
Aura Biosciences, Inc. (AURA) reported Other Operating Activities, Cash Flow Statement of $27.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherOperatingActivitiesCashFlowStatement · last filed 2025-05-15
- Aura Biosciences, Inc. other operating activities, cash flow statement for the quarter ending 2025-03-31 was $27.00K.
- Aura Biosciences, Inc. other operating activities, cash flow statement for the quarter ending 2024-12-31 was $0.00.
- Aura Biosciences, Inc. other operating activities, cash flow statement for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Aura Biosciences, Inc. other operating activities, cash flow statement for the quarter ending 2024-06-30 was $0.00.
- Aura Biosciences, Inc. other operating activities, cash flow statement for fiscal 2024 was -$5.00K.
- Aura Biosciences, Inc. other operating activities, cash flow statement for fiscal 2022 was $224.00K, a 1393.33% increase from fiscal 2021.
- Aura Biosciences, Inc. other operating activities, cash flow statement for fiscal 2021 was $15.00K.
| Period end | Other Operating Activities, Cash Flow Statement 3 month | Other Operating Activities, Cash Flow Statement 3 month as first filed | Other Operating Activities, Cash Flow Statement 6 month | Other Operating Activities, Cash Flow Statement 9 month | Other Operating Activities, Cash Flow Statement 12 month |
|---|---|---|---|---|---|
| 2025-03-31 | $27.00K 10-Q · filed 2025-05-15 | $27.00K derived: sum of 2 quarters · filed 2025-05-15 | $27.00K derived: sum of 3 quarters · filed 2025-05-15 | $27.00K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $0.00 derived: sum of 2 quarters · filed 2025-03-24 | $0.00 derived: sum of 3 quarters · filed 2025-03-24 | -$5.00K 10-K · filed 2025-03-24 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | -$5.00K 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$5.00K 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | -$5.00K 10-Q · filed 2025-05-15 | ||||
| 2023-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.00K 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | $112.00K 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $224.00K 10-K · filed 2023-03-15 | ||||
| 2022-03-31 | $46.00K 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | $15.00K 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |